Danaher Corporation

“Danaher remains one of the better businesses in life sciences and diagnostics, with durable competitive advantages, strong cash generation, and a credible long-term reinvestment playbook. However, the stock already discounts a solid recovery and continued execution, so the current setup looks more like a fair-to-slightly-expensive price for a very good company than an obvious bargain. The main long-term risk is not business fragility but capital allocation slippage through lower-return acquisitions while investors continue to pay a premium multiple.”